We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Taccalonolides Selectively Kill Cancer Cells

By LabMedica International staff writers
Posted on 04 Dec 2011
Drug developers have defined the structural and functional relationship between the taccalonolide class of potential therapeutic agents and the microtubule component tubulin.

The taccalonolides are a class of microtubule stabilizing agents isolated from plants of the genus Tacca. Functionally, they resemble the taxane drug paclitaxel (and docetaxel, a synthetic derivative of the naturally occurring compound paclitaxel), which disrupts microtubule function, inhibiting cell replication. More...
One of the roles of normal microtubules is to aid in the replication of cells, and paclitaxel promotes the formation of microtubules that do not function properly, thus disrupting this function and inhibiting cell replication. Suppression of bone marrow function is the principal adverse side effect associated with paclitaxel treatment.

In the current study, investigators at the University of Texas Health Science Center (San Antonio, USA) sought an explanation at the molecular level as to how the taccalonides interact with and stabilize microtubules.

They reported in the November 1, 2011, online edition of the Journal of the American Chemical Society that they had isolated five new taccalonolides, AC–AF and H2, from one fraction of an ethanol extract of Tacca plantaginea. Taccalonolide AJ, an epoxidation product of taccalonolide B, was generated by semisynthesis. Structures of the compounds were elucidated using a combination of spectroscopic methods, including NMR (nuclear magnetic resonance) and high-resolution mass spectroscopy.

Five of these taccalonolides demonstrated cellular microtubule-stabilizing activities and antiproliferative actions against cancer cells. In mechanistic assays, taccalonolides AF and AJ stimulated the polymerization of purified tubulin, an activity that had not previously been observed for taccalonolides A and B, providing the first evidence that this class of microtubule stabilizers can interact directly with tubulin/microtubules.

“We have been working with these for years with some good results, but never with the potency of paclitaxel,” said senior author Dr. Susan Mooberry, professor of pharmacology at the University of Texas Health Science Center. “Now we have that potency, and we also show for the first time the taccalonolides’ cellular binding site. The taccalonolides stabilize microtubules in cancer cells, but they do not attack healthy cells. We have run normal prostate cells and normal breast cells through these tests, and they do not die. The taccalonolides selectively kill cancer cells.”

Related Links:
University of Texas Health Science Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.